Ligand Pharmaceuticals Income Statement (2010-2026) | LGND

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	78.85M	59.69M	56.40M	36.52M	50.13M	59.22M	50.38M	43.98M	26.37M	32.87M	28.10M	30.98M	41.53M	51.81M	42.81M	45.33M	47.63M	115.46M	59.67M	51.72M
Cost of Revenue (Quarter)	30.59M	11.45M	11.98M	4.70M	12.36M	14.15M	21.61M	3.72M	1.67M	3.48M	1.64M	2.88M	2.91M	2.45M	2.84M	4.85M	2.91M	3.80M	2.99M	3.27M
Gross Profit (Quarter)	48.26M	48.25M	44.42M	31.82M	37.77M	45.07M	28.77M	40.26M	24.70M	29.38M	26.46M	28.10M	38.62M	49.36M	39.98M	40.48M	44.72M	111.66M	56.67M	48.45M
Operating items
Amortization - Intangibles (Quarter)	11.78M	11.83M	-1.17M	8.58M	8.55M	8.57M	8.54M	8.54M	8.54M	8.24M	8.34M	8.19M	8.26M	8.26M	8.30M	8.26M	8.26M	8.10M	8.09M	8.10M
Research & Development (Quarter)	7.48M	7.43M	8.15M	9.18M	8.47M	9.24M	9.20M	6.66M	6.85M	5.53M	5.49M	5.97M	5.35M	5.67M	4.42M	50.09M	6.57M	21.02M	3.51M	2.15M
Selling, General & Administrative (Quarter)	12.41M	10.97M	12.60M	11.93M	12.09M	14.92M	31.13M	10.86M	11.29M	14.66M	15.99M	10.95M	17.62M	24.48M	25.61M	18.80M	20.18M	28.45M	25.03M	20.84M
Restructuring Costs (Quarter)
Other Operating Expenses (Quarter)	34.10M	3.80M	-37.60M	13.28M				12.26M	10.21M	2.12M		11.07M	37.65M			12.66M	12.44M	11.06M	17.29M	11.37M
Operating Expenses (Quarter)	24.94M	34.60M	41.28M	34.38M	41.46M	46.88M	70.48M	29.77M	28.35M	31.91M	31.46M	27.99M	60.63M	48.67M	52.45M	81.55M	39.18M	60.53M	45.82M	34.35M
Operating Income (Quarter)	45.74M	15.71M	37.69M	2.13M	8.66M	12.34M	-20.10M	14.21M	-1.98M	3.08M	-3.36M	2.99M	-19.10M	3.14M	-9.64M	-36.22M	8.44M	54.93M	13.84M	17.37M
EBIT (Quarter)	45.74M	15.71M	37.69M	2.13M	8.66M	12.34M	-20.10M	14.21M	-1.98M	3.08M	-3.36M	2.99M	-19.10M	3.14M	-9.64M	-36.22M	8.44M	54.93M	13.84M	17.37M
Non-operating items
Non Operating Investment Income (Quarter)	-6.86M	1.94M	-13.40M	-12.88M	-1.91M	-0.92M	44.25M	39.53M	3.99M	-13.18M	16.02M	110.77M	-14.26M	2.41M	-23.90M	-12.37M	0.94M	7.80M	22.06M	3.87M
Interest & Investment Income (Quarter)	0.23M	0.17M	0.19M	0.13M	0.30M	0.59M	1.02M	1.44M	2.32M	2.26M	1.69M	2.02M	2.76M	1.35M	1.93M	1.77M	1.62M	3.87M	6.39M	6.66M
Other Non Operating Income (Quarter)	-0.92M	1.89M	-2.13M	2.25M	2.05M	0.68M	-4.98M		-0.87M			-2.19M		-7.81M	-1.45M	0.44M	1.37M	-0.44M	-0.09M	-1.18M
Non Operating Income (Quarter)	-12.44M	-0.45M	-19.81M	-11.28M	-0.00M	0.01M	44.24M	41.33M	5.15M	-15.22M	20.45M	110.46M	-46.29M	-9.48M	-29.56M	-13.96M	2.78M	86.21M	42.94M	-41.63M
Net income details
EBT (Quarter)	33.30M	15.26M	17.88M	-9.14M	8.66M	12.35M	24.14M	55.54M	3.17M	-12.14M	17.10M	113.45M	-65.39M	-6.34M	-39.20M	-50.18M	11.22M	141.14M	56.78M	-24.26M
Tax Provisions (Quarter)	2.58M	1.54M	4.08M	3.79M	-3.94M	2.71M	38.67M	11.92M	0.88M	-1.87M	-1.09M	27.31M	-13.48M	0.83M	-8.11M	-7.73M	6.38M	23.86M	12.00M	-10.91M
Profit After Tax (Quarter)	30.73M	13.72M	-3.19M	-15.38M	-0.90M	0.40M	-17.48M	41.95M	2.29M	-10.27M	18.19M	86.14M	-51.91M	-7.17M	-31.09M	-42.45M	4.85M	117.27M	44.78M	-13.35M
Income from Non-Controlling Interests (Quarter)	-0.01M			-0.11M	-0.04M			0.05M
Income from Continuing Operations (Quarter)	30.73M	13.72M	13.80M	-12.93M	12.60M	9.64M	-14.53M	43.61M	2.29M	-10.27M	18.19M	86.14M	-51.91M	-7.17M	-31.09M	-42.45M	4.85M	117.27M	44.78M	-13.35M
Income from Discontinued Operations (Quarter)
Consolidated Net Income (Quarter)	-5.72M	-6.62M	-2.22M	-2.46M	-13.49M	-9.24M	-2.95M	-1.67M							-31.09M	-42.45M	4.85M	117.27M	44.78M	-13.35M
Income towards Parent Company (Quarter)	-5.72M	-6.62M	-2.22M	-2.46M	-13.49M	-9.24M	-2.95M	-1.67M							-31.09M	-42.45M	4.85M	117.27M	44.78M	-13.35M
Net Income towards Common Stockholders (Quarter)	-5.72M	-6.62M	-2.22M	-2.46M	-13.49M	-9.24M	-2.95M	-1.67M							-31.09M	-42.45M	4.85M	117.27M	44.78M	-13.35M
Additional items
EPS (Basic) (Quarter)	-0.34	-0.40	-0.13	-0.15	-0.80	-0.55	-0.17	-0.10							-1.70	-2.21	0.25	5.99	2.32	-0.67
EPS (Diluted) (Quarter)	-0.33	-0.39	-0.13	-0.15	-0.80	-0.54	-0.17	-0.09							-1.70	-2.21	0.24	5.68	2.21	-0.67
Shares Outstanding (Quarter)	16.66M	16.69M	16.63M	16.82M	16.87M	16.89M	16.87M	17.06M	17.28M	17.38M	17.30M	17.73M	18.03M	18.42M	18.29M	19.19M	19.33M	19.58M	19.34M	19.88M
Shares Outstanding (Diluted) (Quarter)	17.17M	17.14M	17.25M	16.82M	16.87M	17.13M	16.87M	17.97M	17.73M	17.38M	17.76M	18.12M	18.03M	18.42M	18.29M	19.19M	19.93M	20.63M	20.29M	19.88M
Shares Outstanding (Entity) (Quarter)	16.68M	16.71M	16.77M	16.86M	16.88M	16.89M	16.95M	17.13M	17.35M	17.42M	17.56M	17.92M	18.10M	18.76M	19.11M	19.28M	19.41M	19.66M	19.77M	20.03M
EBITDA (Quarter)	45.74M	15.71M	37.69M	2.13M	8.66M	12.34M	-20.10M	14.21M	-1.98M	3.08M	-3.36M	2.99M	-19.10M	3.14M	-9.64M	-36.22M	8.44M	54.93M	13.84M	17.37M
Interest Expenses (Quarter)	4.88M	4.44M	17.88M	0.79M	0.44M	0.33M	0.66M	0.24M	4.34M	0.00M	0.13M	0.14M	1.27M	0.74M	0.88M	0.87M	1.15M	14.90M	4.42M	14.90M
Tax Rate (Quarter)	7.74%	10.07%	22.83%	-41.39%	-45.47%	21.93%	160.21%	21.47%	27.78%	15.41%	-6.38%	24.07%	20.61%	-13.14%	20.69%	15.40%	56.81%	16.91%	21.13%	44.99%

Research Tools

Developers

Ligand Pharmaceuticals Income Statement (2010-2026) | LGND

Research Tools

Developers

Ligand Pharmaceuticals Income Statement (2010-2026) | LGND

Create an account

Sign In

Reset Password